Literature DB >> 24307779

Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C.

Ulrich Spengler1, Hans Dieter Nischalke, Jacob Nattermann, Christian P Strassburg.   

Abstract

Hepatitis C virus (HCV) frequently elicits only mild immune responses so that it can often establish chronic infection. In this case HCV antigens persist and continue to stimulate the immune system. Antigen persistence then leads to profound changes in the infected host's immune responsiveness, and eventually contributes to the pathology of chronic hepatitis. This topic highlight summarizes changes associated with chronic hepatitis C concerning innate immunity (interferons, natural killer cells), adaptive immune responses (immunoglobulins, T cells, and mechanisms of immune regulation (regulatory T cells). Our overview clarifies that a strong anti-HCV immune response is frequently associated with acute severe tissue damage. In chronic hepatitis C, however, the effector arms of the immune system either become refractory to activation or take over regulatory functions. Taken together these changes in immunity may lead to persistent liver damage and cirrhosis. Consequently, effector arms of the immune system will not only be considered with respect to antiviral defence but also as pivotal mechanisms of inflammation, necrosis and progression to cirrhosis. Thus, avoiding Scylla - a strong, sustained antiviral immune response with inital tissue damage - takes the infected host to virus-triggered immunopathology, which ultimately leads to cirrhosis and liver cancer - the realm of Charybdis.

Entities:  

Keywords:  CD4+ T helper cells; Hepatic stellate cells; Hepatitis C; Hepatocytes; Immunoglobulin; Interferon; Natural killer cells; Regulatory T cells; Retinoic acid inducible gene-I; Toll like receptors

Mesh:

Substances:

Year:  2013        PMID: 24307779      PMCID: PMC3848133          DOI: 10.3748/wjg.v19.i44.7852

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  185 in total

Review 1.  Natural killer cells in viral hepatitis: facts and controversies.

Authors:  Mario U Mondelli; Stefania Varchetta; Barbara Oliviero
Journal:  Eur J Clin Invest       Date:  2010-06-29       Impact factor: 4.686

2.  Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C.

Authors:  Tarik Asselah; Ivan Bièche; Ingrid Laurendeau; Valérie Paradis; Dominique Vidaud; Claude Degott; Michelle Martinot; Pierre Bedossa; Dominique Valla; Michel Vidaud; Patrick Marcellin
Journal:  Gastroenterology       Date:  2005-12       Impact factor: 22.682

3.  NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner.

Authors:  Andreas Glässner; Marianne Eisenhardt; Benjamin Krämer; Christian Körner; Martin Coenen; Tilman Sauerbruch; Ulrich Spengler; Jacob Nattermann
Journal:  Lab Invest       Date:  2012-03-26       Impact factor: 5.662

4.  T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection.

Authors:  Tobias Boettler; Hans Christian Spangenberg; Christoph Neumann-Haefelin; Elisabeth Panther; Simonetta Urbani; Carlo Ferrari; Hubert E Blum; Fritz von Weizsäcker; Robert Thimme
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  IL28B genotype and the expression of ISGs in normal liver.

Authors:  Zoe Raglow; Carly Thoma-Perry; Richard Gilroy; Yu-Jui Y Wan
Journal:  Liver Int       Date:  2013-03-24       Impact factor: 5.828

6.  Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells.

Authors:  Nan Wang; Yuqiong Liang; Santhana Devaraj; Jie Wang; Stanley M Lemon; Kui Li
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

7.  Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Authors:  Susanna Naggie; Anu Osinusi; Antonios Katsounas; Richard Lempicki; Eva Herrmann; Alexander J Thompson; Paul J Clark; Keyur Patel; Andrew J Muir; John G McHutchison; Joerg F Schlaak; Martin Trippler; Bhavana Shivakumar; Henry Masur; Michael A Polis; Shyam Kottilil
Journal:  Hepatology       Date:  2012-07-02       Impact factor: 17.425

8.  Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.

Authors:  Golo Ahlenstiel; Rachel H Titerence; Christopher Koh; Birgit Edlich; Jordan J Feld; Yaron Rotman; Marc G Ghany; Jay H Hoofnagle; T Jake Liang; Theo Heller; Barbara Rehermann
Journal:  Gastroenterology       Date:  2009-09-10       Impact factor: 22.682

9.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

10.  The CXCR3(+)CD56Bright phenotype characterizes a distinct NK cell subset with anti-fibrotic potential that shows dys-regulated activity in hepatitis C.

Authors:  Marianne Eisenhardt; Andreas Glässner; Benjamin Krämer; Christian Körner; Bernhard Sibbing; Pavlos Kokordelis; Hans Dieter Nischalke; Tilman Sauerbruch; Ulrich Spengler; Jacob Nattermann
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

View more
  2 in total

Review 1.  Gut microbiota modulate the immune effect against hepatitis B virus infection.

Authors:  D Xu; Y Huang; J Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-14       Impact factor: 3.267

2.  Targeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver.

Authors:  Julia Volckmar; Marcus Gereke; Thomas Ebensen; Peggy Riese; Lars Philipsen; Stefan Lienenklaus; Dirk Wohlleber; Robert Klopfleisch; Sabine Stegemann-Koniszewski; Andreas J Müller; Achim D Gruber; Percy Knolle; Carlos A Guzman; Dunja Bruder
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.